Headlines about TRACON Pharmaceuticals (NASDAQ:TCON) have been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. TRACON Pharmaceuticals earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 45.0188338392687 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the headlines that may have impacted Accern’s rankings:
- TRACON Pharmaceuticals Announces Positive Data from Ongoing Phase 1b/2 Trial of TRC105 in Hepatocellular Carcinoma Patients (finance.yahoo.com)
- TRACON Pharmaceuticals Reports Granting of Inducement Awards (finance.yahoo.com)
- Brokerages Expect TRACON Pharmaceuticals Inc (TCON) Will Announce Earnings of -$0.45 Per Share (americanbankingnews.com)
- Research Analysts at Liberum Capital Kept the Same their “Buy” rating for Hotel Chocolat Group Ltd (LON:HOTC). The … – Hill Country Times (hillcountrytimes.com)
- In For the Long Haul? TRACON Pharmaceuticals, Inc. (NasdaqGM:TCON) Quant PI at 1.31818 – SCY News (scynews.com)
Separately, Zacks Investment Research downgraded TRACON Pharmaceuticals from a “buy” rating to a “hold” rating and set a $4.00 target price for the company. in a research note on Friday, January 5th.
TRACON Pharmaceuticals (NASDAQ:TCON) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.07 EPS for the quarter, topping the consensus estimate of ($0.25) by $0.32. TRACON Pharmaceuticals had a negative return on equity of 83.43% and a negative net margin of 201.21%. The business had revenue of $7.50 million during the quarter, compared to the consensus estimate of $7.60 million. equities research analysts predict that TRACON Pharmaceuticals will post -1.21 EPS for the current fiscal year.
WARNING: This report was published by Ticker Report and is owned by of Ticker Report. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://www.tickerreport.com/banking-finance/3146090/tracon-pharmaceuticals-tcon-earning-somewhat-positive-media-coverage-analysis-finds.html.
TRACON Pharmaceuticals Company Profile
TRACON Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company’s research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring).
Receive News & Ratings for TRACON Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.